



7 January, 2021

PRESS RELEASE FOR IMMEDIATE USE

**Dechra acquires Isoflurane and Sevoflurane
from Halocarbon Life Sciences**

Dechra is pleased to announce the acquisition of the veterinary approved Isoflurane[®], USP Inhalant Anesthetic and Sevoflurane[®], USP Inhalant Anesthetic from Halocarbon.

Mike Eldred, President of Dechra North America, stated, “These products are utilized daily in veterinary hospitals and complement our current sedative and anesthetic product range. We are excited to continue to grow and expand our veterinary surgical suite and anesthetic portfolio and offer high quality products to the veterinary community.”

Dechra will be launching the veterinary branded Isoflurane and Sevoflurane in the first quarter of 2022.

About Dechra:

Dechra’s companion animal portfolio focuses on endocrinology, dermatology, ophthalmology, anesthesia, fluid therapy, pain management, joint health support, and dental care. Our brands include Vetoryl[®] Capsules (trilostane), Zycortal[®] Suspension (desoxycorticosterone pivalate injectable suspension), Felimazole[®] Coated Tablets (methimazole), the Vetivex[®] line of parenteral fluids, and Phycox[®] joint health supplements. Osurnia[®] (florfenicol, terbinafine, betamethasone acetate) and the TrizUltra+Keto[®], MiconHex+Triz[®], MalAcetic[®], and oral anti-infective product lines, including Marboquin[®] (marbofloxacin) Tablets and Amoxicillin and Clavulanate Potassium for Oral Suspension, spotlight the dermatology offerings. And the recent addition of Mirataz[®] (mirtazapine transdermal ointment), Porus[®] One, and Redonyl[®] Ultra Feline to the portfolio supports the underserved feline market.

Contact:

Mike Eldred
President, North American Operations
Dechra Veterinary Products
Mike.Eldred@Dechra.com

Doug Hubert
Vice President, Sales and Marketing
Dechra Veterinary Products
Doug.Hubert@Dechra.com